BioPharma Resources

Drug Trial Radar · NCT07775300

A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment With Brenipatide in Delaying Time to Relapse Compared With Placebo in Adult Participants With Major Depressive Disorder (RENEW-MDD- 2)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Aug 14, 2026

Primary completion

Dec 2028

Study completion Feb 2029

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Aug 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms. The trial is divided into four periods as follows: a screening period that will last approximately 1 month, a treatment period and a post- treatment period that combined will last a minimum of 12 months, and the safety follow up period that will last approximately 2 months. The duration of study participation may vary and may be shortened if depression symptoms worsen or if withdrawal from the study occurs for any reason.

Conditions

  • Depressive Disorder, Major

Interventions

  • BrenipatideDrug

    Administered SC.

  • PlaceboDrug

    Administered SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Relapse Defined as the Number of Days from Randomization to Date on Which the Participant Meets Any Relapse Criterion of Major Depressive Disorder (MDD)Time frame: From Randomization in Double-Blind Adjunctive Treatment to First Relapse For at Least 12 Months

Locations

170 sites in 15 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham - School of Medicine

    Birmingham, Alabama · Recruiting

  • NoesisPharma, LLC

    Phoenix, Arizona · Recruiting

  • Irvine Clinical Research

    Irvine, California · Recruiting

  • Healthy Brain Clinic

    Long Beach, California · Not yet recruiting

  • Oakland Clinical

    Oakland, California · Recruiting

  • Concierge Clinical Trials

    Valley Village, California · Recruiting

  • JEM Research Institute

    Atlantis, Florida · Recruiting

  • Bradenton Research Center, Inc.

    Bradenton, Florida · Recruiting

  • Key Clinical Research

    Bradenton, Florida · Recruiting

  • NextPhase Research Florida - Hollywood

    Hollywood, Florida · Recruiting

  • Miami Jewish health

    Miami, Florida · Not yet recruiting

  • Quantix Research - Miami - Southwest 72nd Street

    Miami, Florida · Recruiting

  • Diverse Clinical Research

    Miami, Florida · Recruiting

  • CLA Research

    Naples, Florida · Recruiting

  • Health Synergy Clinical Research

    West Palm Beach, Florida · Recruiting

  • CenExel iResearch, LLC

    Decatur, Georgia · Not yet recruiting

  • AGILE Clinical Research Trials, LLC

    Sandy Springs, Georgia · Recruiting

  • Charter Research - Chicago

    Chicago, Illinois · Recruiting

  • Pharmasite Research, Inc.

    Baltimore, Maryland · Recruiting

  • Adams Clinical Boston

    Boston, Massachusetts · Recruiting

  • Adams Clinical Watertown

    Watertown, Massachusetts · Recruiting

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division

    Troy, Michigan · Recruiting

  • Be Well Clinical Studies - Omaha

    Omaha, Nebraska · Recruiting

  • Adams Clinical Bronx

    The Bronx, New York · Recruiting

  • Adams Clinical Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Penn Medicine: University of Pennsylvania Health System

    Philadelphia, Pennsylvania · Recruiting

  • Suburban Research Associates

    West Chester, Pennsylvania · Recruiting

  • FutureSearch Trials of Neurology

    Austin, Texas · Not yet recruiting

  • Gadolin Research

    Beaumont, Texas · Recruiting

  • Adams Clinical Dallas

    DeSoto, Texas · Recruiting

  • The University of Texas Rio Grande Valley

    Harlingen, Texas · Not yet recruiting

  • Olympus Clinical Research

    Katy, Texas · Recruiting

  • Boeson Research - Provo

    Provo, Utah · Recruiting

  • Northwest Clinical Research Center

    Bellevue, Washington · Recruiting

  • Ramsay Clinic New Farm

    Brisbane, Australia · Not yet recruiting

  • Paratus Clinical Research Canberra

    Bruce, Australia · Not yet recruiting

  • NeuroCentrix

    Carlton, Australia · Not yet recruiting

  • Lyell McEwin Hospital

    Elizabeth Vale, Australia · Not yet recruiting

  • Barwon Health

    Geelong, Australia · Not yet recruiting

  • Multidisciplinary Alfred Psychiatry Research Centre

    Melbourne, Australia · Not yet recruiting

Showing 40 of 170 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.